Pharmaceutical innovation and its crisis: drug markets, screening, and the dialectics of value - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue BioSocieties Année : 2021

Pharmaceutical innovation and its crisis: drug markets, screening, and the dialectics of value

Résumé

This article explores recent debates on innovation in the drug sector, focusing on the ways in which the articulation of use value and exchange value operates in the hegemonic-Northern-form of pharmaceutical capitalism. Taking the category 'crisis of innovation' as an entry point and engaging with the economics literature in which it has been discussed for nearly twenty years, this paper uses the vast historiography of post-WWII pharmacy to propose a critical historical understanding of the crisis. It argues that the features to which the crisis discourses point originate in the long-term contradictions between use value and exchange that affect the dominant regime of pharmaceutical innovation, i.e., the screening regime of research and development. These tensions have accumulated over the past two decades and become more visible, leading to a new reading of the present turn toward bio-capital, i.e., toward biotechnology and a more speculative (financial) economy of pharmacy. The last section of the paper discusses the theoretical implications of this hypothesis.
Fichier principal
Vignette du fichier
2b-Innovation and its others-Resubmission.pdf (602.88 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03978380 , version 1 (06-02-2024)

Identifiants

Citer

Jean-Paul Gaudilliere. Pharmaceutical innovation and its crisis: drug markets, screening, and the dialectics of value. BioSocieties, 2021, 16 (3), pp.411-432. ⟨10.1057/s41292-021-00235-7⟩. ⟨hal-03978380⟩
8 Consultations
42 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More